Equities analysts predict that Insmed, Inc. (NASDAQ:INSM) will post earnings of ($0.69) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Insmed’s earnings. The highest EPS estimate is ($0.63) and the lowest is ($0.74). Insmed posted earnings per share of ($0.61) during the same quarter last year, which suggests a negative year over year growth rate of 13.1%. The business is scheduled to report its next earnings report on Thursday, November 2nd.
On average, analysts expect that Insmed will report full year earnings of ($2.68) per share for the current year, with EPS estimates ranging from ($2.79) to ($2.60). For the next year, analysts expect that the business will report earnings of ($2.13) per share, with EPS estimates ranging from ($2.75) to ($1.06). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Insmed.
Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.09).
Several research analysts recently issued reports on INSM shares. Leerink Swann lifted their target price on Insmed from $27.00 to $36.00 and gave the company an “outperform” rating in a research report on Tuesday, September 5th. BidaskClub cut Insmed from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research cut Insmed from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. ValuEngine cut Insmed from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. Insmed has a consensus rating of “Buy” and an average target price of $34.50.
In other Insmed news, Director Donald J. Hayden, Jr. sold 45,000 shares of the business’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $29.67, for a total value of $1,335,150.00. Following the transaction, the director now owns 71,131 shares of the company’s stock, valued at $2,110,456.77. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Melvin Md Sharoky sold 50,000 shares of the business’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $27.37, for a total value of $1,368,500.00. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.
Hedge funds have recently bought and sold shares of the business. BNP Paribas Arbitrage SA boosted its position in Insmed by 666.7% in the second quarter. BNP Paribas Arbitrage SA now owns 7,498 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 6,520 shares during the last quarter. SG Americas Securities LLC purchased a new position in Insmed in the second quarter worth $129,000. UBS Asset Management Americas Inc. purchased a new position in Insmed in the second quarter worth $187,000. Driehaus Capital Management LLC purchased a new position in Insmed in the first quarter worth $192,000. Finally, Virtu KCG Holdings LLC purchased a new position in Insmed in the second quarter worth $201,000. 73.08% of the stock is currently owned by institutional investors and hedge funds.
Insmed (NASDAQ:INSM) traded up 0.4952% during trading on Tuesday, hitting $28.4301. 112,389 shares of the stock traded hands. The stock’s market cap is $1.77 billion. Insmed has a 52 week low of $10.21 and a 52 week high of $31.39. The firm’s 50-day moving average is $17.50 and its 200 day moving average is $17.06.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.